PB 48 of 2025
I, Melanie Finn, Acting Assistant Secretary of the Department of Health, Disability and Ageing make the following instrument.
Dated 17 June 2025
Melanie Finn
Acting Assistant Secretary
Digital and Service Design Branch
Medicare Benefits and Digital Health Division
Department of Health, Disability and Ageing
1 Name
2 Commencement
3 Authority
4 Definitions ............................................1
5 Prescribed requirements for electronic medication charts under the Regulations
6 Schedules.............................................2
Schedule 1 — Information Requirements 2
Schedule 2 — System Functionality 11
Schedule 3 — Copy of an Electronic Medication Chart 14
Schedule 4 — Repeals 18
(1) This instrument is the National Health (Pharmaceutical Benefits) Electronic National Residential Medication Charts Approval Instrument 2025.
(2) This instrument may also be cited as PB 48 of 2025.
This instrument commences the day after this instrument is registered.
This instrument is made under section 12A, paragraph 41(5)(b) and subsection 45(9) of the National Health (Pharmaceutical Benefits) Regulations 2017.
4 Definitions
Note: A number of expressions used in this instrument are defined in section 5 of the Regulations, including the following:
(a) authority approval number;
(b) electronic medication chart system.
In this instrument:
PBS prescriber has the same meaning as in Part VII of the National Health Act 1953.
pharmaceutical benefit has the same meaning as in Part VII of the National Health Act 1953.
pharmaceutical benefits scheme (PBS) has the same meaning as in Part VII of the National Health Act 1953.
Regulations means the National Health (Pharmaceutical Benefits) Regulations 2017.
repatriation pharmaceutical benefit (RPBS) has the same meaning as in Part VII of the National Health Act 1953.
residential care has the same meaning as in the Aged Care Act 1997.
residential care service has the same meaning as in the Aged Care Act 1997.
5 Prescribed requirements for electronic medication charts under the Regulations
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Electronic Medication Chart Information Requirements - PBS/RPBS Electronic Medication Chart prescriptions for persons receiving treatment in or at a residential care service at which the person is receiving residential care.
(a) the patient's allergies, including:
(b) the patient's adverse drug reactions, including:
(a) weight at a point in time; and
(b) sedation scores.
4. Residential care services
(a) business name; and
(b) business address; and
(c) Residential Aged Care Service ID.
5.1 The information requirements for the period of validity of the electronic medication chart must not exceed a period of six months.
5.2 The information requirements for the period of validity of the electronic medication chart must include the following details of the chart:
(a) commencement date; and
(b) expiry date.
6.1 The information requirements for a PBS prescriber must include the following details of the PBS prescriber:
(a) full name; and
(b) address; and
(c) PBS prescriber number; and
(d) PBS prescribers Healthcare Provider Identifier - Individual (HPI-I); and
(e) PBS Prescribers Healthcare Provider Identifier - Organisation (HPI-O); and
(f) contact details sufficient to make contact with the PBS prescriber at any time.
7.1 The information requirements for regularly administered and short-term pharmaceutical benefits must include the following:
(a) particulars sufficient to identify the pharmaceutical benefit, in line with Pharmaceutical Benefits Scheme requirements, pharmaceutical dose, form and strength; and
(b) the pharmaceutical benefit's:
(i) date and time of prescribing; and
(ii) dose; and
(iii) route of administration; and
(iv) frequency of administration; and
(v) site of administration (if appropriate); and
(vi) indication for prescribing; and
(vii) PBS Authority Approval Number/s if required; and
(c) the day, month and year of the date (the start date) to start administering the pharmaceutical benefit; and
(d) the start time for administration (if necessary); and
(e) the day, month and year of the date (the stop date) to stop administering the pharmaceutical benefit; and
(f) specified duration or indication that medicine is to be supplied for duration of chart; and
(g) brand substitution indicator
(h) Authority Prescription Number; and
(i) Closing the Gap (CTG); and
(j) PBS/RPBS; and
(k) Streamlined Authority; and
(l) additional instructions (if any) to be added by the medical practitioner, expressed as 'Additional Instructions'.
7.2 Information requirements for a regularly administered pharmaceutical benefit must also include a record of each administration of the benefit, including the following:
(a) pharmaceutical benefit; and
(b) form; and
(c) strength; and
(d) dose; and
(e) route; and
(f) date and time; and
(g) credentials of nurse administering the pharmaceutical benefit.
7.3 Information requirements for a regularly administered pharmaceutical benefit must also include a record of the administration of the benefit if the benefit has been administered by means of a multi-dose pack with the date and time of administration recorded based on accepted naming conventions such as:
(a) breakfast; or
(b) lunch; or
(c) dinner; or
(d) bedtime.
8.1 The information requirements for a pharmaceutical benefit that is insulin and is not required to be administered PRN (as required) must include the following:
(a) particulars sufficient to identify the pharmaceutical benefit, by active ingredient and brand name, form, strength and units; and
(b) the pharmaceutical benefit's:
(i) date and time of prescribing; and
(ii) route of administration; and
(iii) time for administration; and
(iv) PBS Authority Approval Number/s (if required); and
(c) the day, month and year of the date (the start date) to start administering the pharmaceutical benefit; and
(d) the day, month and year of the date (the stop date) to stop administering the pharmaceutical benefit; and
(e) specified duration or indication that medicine is to be supplied for duration of chart; and
(f) Authority Prescription Number; and
(g) Closing the Gap (CTG); and
(h) PBS/RPBS; and
(i) additional instructions (if any) to be added by the medical practitioner, expressed as 'Additional Instructions'; and
(j) Blood Glucose Level (BGL) range for administration; and
(k) Blood Glucose Level recording and charting of:
(i) date and time; and
(ii) Blood Glucose Level.
8.2 Information requirements for a regularly administered pharmaceutical benefit must also include a record of each administration of the benefit including the following:
(a) date and time; and
(b) units/dose; and
(c) credentials of the first nurse authorising and administering the pharmaceutical benefit; and
(d) credentials of the second nurse authorising and administering the pharmaceutical benefit.
9.1 The information requirements for a pharmaceutical benefit that is insulin required to be administered PRN (as required) must include the following:
(a) particulars sufficient to identify the pharmaceutical benefit, by active ingredient and brand name, form, strength and units; and
(b) the pharmaceutical benefit's:
(i) date and time of prescribing; and
(ii) route of administration; and
(c) the day, month and year of the date (the start date) to start administering the pharmaceutical benefit; and
(d) the day, month and year of the date (the stop date) to stop administering the pharmaceutical benefit; and
(e) specified duration or indication that medicine is to be supplied for duration of chart; and
(f) Closing the Gap (CTG); and
(g) PBS/RPBS; and
(h) the maximum dose in 24 hours; and
9.2 Information requirements for a regularly administered pharmaceutical benefit must also include a record of each administration of the benefit including the following:
(a) date and time; and
(b) units/dose; and
(c) Blood Glucose Level recording and charting of:
(i) date and time; and
(ii) Blood Glucose Level.
(d) credentials of the first Nurse authorising and administering the pharmaceutical benefit.
10.1 The information requirements for a pharmaceutical benefit, other than insulin, that is required to be administered PRN (as required) must include the following:
(a) particulars sufficient to identify the pharmaceutical benefit, in line with Pharmaceutical Benefits Scheme Prescribing requirements, pharmaceutical dose, form and strength; and
(b) the pharmaceutical benefit's:
(i) date and time of prescribing; and
(ii) dose; and
(iii) route of administration; and
(iv) frequency of administration; and
(v) site of administration (if appropriate); and
(vi) indication for prescribing; and
(vii) PBS Authority Approval Number/s if required; and
(c) the indication for administration of the pharmaceutical benefit; and
(d) maximum individual dose or range; and
(e) minimum interval between administrations; and
(f) maximum dose in 24 hours; and
(g) the day, month and year of the date (the start date) to start administering the pharmaceutical benefit; and
(h) the day, month and year of the date (the stop date) to stop administering the pharmaceutical benefit; and
(i) specified duration or indication that medicine is to be supplied for duration of chart; and
(j) brand substitution indicator; and
(k) Authority Prescription Number; and
(l) Closing the Gap (CTG); and
(m) PBS/RPBS; and
(n) Streamlined Authority; and
(o) additional instructions (if any) to be added by the medical practitioner, expressed as 'Additional Instructions'.
10.2 Information requirements for a regularly administered pharmaceutical benefit must also include a record of each administration of the benefit including:
(a) pharmaceutical benefit; and
(b) form; and
(c) strength; and
(d) dose administered; and
(e) route; and
(f) reason for administration of the pharmaceutical benefit; and
(g) date and time; and
(h) credentials of Nurse administering the pharmaceutical benefit; and
(i) outcome or effect of medicine and time observation was made; and
(j) credentials of Nurse recording the observation.
11.1 The information requirements for a pharmaceutical benefit, other than insulin, that is required to be administered at a variable dose must include the following:
(a) particulars sufficient to identify the pharmaceutical benefit, in line with Pharmaceutical Benefits Scheme Prescribing requirements, pharmaceutical dose, form and strength; and
(b) the pharmaceutical benefit's:
(i) date and time of prescribing; and
(ii) dose; and
(iii) route of administration; and
(iv) frequency of administration; and
(v) site of administration (if appropriate); and
(vi) indication for prescribing; and
(vii) PBS Authority Approval Number/s if required; and
(c) the day, month and year of the date (the start date) to start administering the pharmaceutical benefit; and
(d) the start time for administration (if necessary); and
(e) the day, month and year of the date (the stop date) to stop administering the pharmaceutical benefit; and
(f) specified duration or indication that medicine is to be supplied for duration of chart; and
(g) brand substitution indicator; and
(h) Authority Prescription Number; and
(i) Closing the Gap (CTG); and
(j) PBS/RPBS; and
(k) Streamlined Authority; and
(l) additional instructions (if any) to be added by the medical practitioner, expressed as' Additional Instructions'.
11.2 Information requirements for a regularly administered pharmaceutical benefit must also include a record of each administration of the benefit with the following details:
(a) pharmaceutical benefit; and
(b) form; and
(c) strength; and
(d) dose; and
(e) route; and
(f) date and time; and
(g) dose administered; and
(h) credentials of the first nurse authorising and administering the pharmaceutical benefit; and
(i) credentials of the second nurse authorising and administering the pharmaceutical benefit.
12.1 The additional information requirements for prescribing of a pharmaceutical benefit that is an infusion must include additional instructions to be added by the medical practitioner, expressed as 'Additional Instructions' to capture information of the pharmaceutical benefit, such as:
(a) infusion instructions; and
(b) infusion liquid; and
(c) rate/time; and
(d) maximum hourly rate; and
(e) daily limits; or
12.2 The system functionality requirements covered in paragraph 9 of Schedule 2 of this instrument.
13.1 The additional information requirements for prescribing of a pharmaceutical benefit that is a Transdermal Patch must include additional instructions to be added by the medical practitioner, expressed as 'Additional Instructions' to capture information of the pharmaceutical benefit, such as:
(a) day for application; and
(b) instructions for safe removal; and
(c) placement of patch; and
(d) minimum 'patch free' time.
14.1 The additional information requirements for prescribing and administration of a Schedule 8 (controlled) pharmaceutical benefit must include the credentials of the second nurse authorising and administering the pharmaceutical benefit
15.1 The information requirements for a pharmaceutical benefit that is a nutritional supplement must include the following:
(a) particulars sufficient to identify the pharmaceutical benefit, including the name and strength, expressed as 'nutritional supplement'; and
(b) the pharmaceutical benefit's:
(i) date of prescribing; and
(ii) dose; and
(iii) route of administration; and
(iv) frequency of administration; and
(v) Indication for use (when relevant); and
(c) the day, month and year of the date (the start date) to start administering the pharmaceutical benefit; and
(d) the day, month and year of the date (the stop date) to stop administering the pharmaceutical benefit; and
(e) specified duration or indication that medicine is to be supplied for duration of chart; and
(f) brand substitution indicator; and
(g) Closing the Gap (CTG); and
(h) PBS/RPBS; and
(i) additional instructions (if any) to be added by the PBS prescriber, expressed as 'Additional Instructions'.
Electronic Medication Chart System Functionality - PBS/RPBS Electronic Medication Chart prescriptions for persons receiving treatment in or at a residential care service at which the person is receiving residential care.
2.1 The system functionality allergies and adverse reactions for a patient who is receiving residential care in a residential care service must:
(a) allow the user to record administration-related ADRs; and
(b) ensure that allergies and ADRs are visible on all system screens from which medicines are prescribed, reviewed, supplied or administered.
3.1 The system functionality for the six month period of validity of the electronic medication chart must:
(a) alert all users when chart is nearing expiry - at least three weeks before expiry; and
(b) not allow for further prescribing, supply or administration of pharmaceutical benefits past the expiry date.
4.1 The system functionality for a PBS prescriber must:
(a) validate the PBS Prescribers Australian Health Practitioner Regulation Agency (AHPRA) number; and
(b) validate the PBS Prescribers Healthcare Provider Identifier - Individual (HPI-I); and
(c) validate the PBS Prescribers Healthcare Provider Identifier - Organisation (HPI-O).
5.1 The system functionality for a regularly administered and short-term pharmaceutical benefit must ensure:
(a) that systems that do not default to add Brand; and
(b) for short-term medicines, that the system must only enable administration for the duration specified by the prescriber.
6.1 The system functionality for pharmaceutical benefit that is insulin and is not required to be administered PRN (as required) must not default to add Brand.
7.1 The system functionality for PRN pharmaceutical benefits must ensure that systems must not default to add Brand.
8.1 The system functionality for a pharmaceutical benefit, other than insulin, that is required to be administered at a variable dose must:
(a) enable prescribing based on:
(i) age; and
(ii) weight; and
(b) capture the dates that dose changes will apply; and
(c) support variable dosing regimens including tapering regimens and dose rounding; and
(d) must not default to add Brand.
9.1 The system functionality requirements for prescribing of a pharmaceutical benefit that is an infusion must include:
(a) indicator to notify when an infusion chart outside of the eNRMC chart is active for the resident; and
(b) additional instructions field to be added by the medical practitioner, expressed as 'Additional Instructions' to capture information and details, such as the infusion chart type.
9.2 If section 12.1 of Schedule 1 applies, Section 9.1 does not apply.
10.1 The system functionality for a Schedule 8 (controlled drugs) pharmaceutical benefit must:
(a) restrict prescribing of pharmaceutical benefit to maximum quantity as per the Regulations; and
(b) restrict prescribing and supply of pharmaceutical benefits as per the Regulations and not be permitted for duration of the medication chart.
11.1 The Security and Validation system functionality for electronic medication charts must:
(a) maintain audit log records of all medication management transactions, including the following:
(i) all changes to medicine orders, and the dose and route of the administered medicine; and
(ii) all changes to annotations; and
(iii) the date and time of each transaction; and
(iv) the name, designation and registration number of the user undertaking each transaction; and
(b) ensure all medicine orders and changes to them can be audited and attributed to the person(s) who made the changes.
12.1 The additional system functionality requirements for electronic medication charts must include the following:
(a) ensure all suppliers (contracted and non-contracted) have access to the full list of medicine orders on the electronic medication chart in real time; and
(b) systems must only display current medicines and ceased medicines for the current medication chart duration; and
(c) enable generation of a copy of an electronic medication chart which:
(i) meets information requirements as specified by the Secretary; and
(ii) each page is date and time stamped.
Copy of a Medication Chart Information Requirements to support supply from a copy of a PBS/RPBS Electronic Medication Chart prescription for persons receiving treatment in or at a residential care service at which the person is receiving residential care, in urgent situations.
2.1 The copy of a chart requirements for allergies and drug reactions must be easily readable and clearly visible to a person looking at any page of the medication chart, and must include the following:
(a) the patient's allergies, including:
3.1 The copy of a chart requirements for a residential care service must include the following details of the residential care service:
(a) business name; and
(b) business address; and
(c) Residential Aged Care Service ID.
4.1 The copy of a chart requirements for current pharmaceutical benefits is provided below:
(a) The information for a regularly administered pharmaceutical benefit must include:
(b) The information for a PRN administered pharmaceutical benefit must include:
(c) The information for a short-term pharmaceutical benefit must include:
(d) The information for a variable dose pharmaceutical benefit must include:
5.1 The copy of a chart requirements for recently ceased pharmaceutical benefits within the current chart duration must include the following:
(a) particulars sufficient to identify the pharmaceutical benefit, including the name, pharmaceutical dose, form and strength, expressed as 'medicine/form/strength'; and
(b) dose; and
(c) route of administration; and
(d) frequency of administration; and
(e) prescriber details to satisfy paragraph 6 of Schedule 1; and
(f) date ceased; and
(g) reason for cessation (if known).
6.1 The copy of a chart requirements for all pharmaceutical benefit administration must include the following:
(a) commencement date; and
(b) cessation date; and
(c) administration considerations.
7.1 The copy of a chart requirements for a pharmaceutical benefit that is a nutritional supplement must include the following:
(a) particulars sufficient to identify the pharmaceutical benefit, including the name and strength, expressed as 'nutritional supplement'; and
(b) date of prescribing; and
(c) dose; and
(d) route of administration; and
(e) frequency of administration; and
(f) prescriber details to satisfy paragraph 6 of Schedule1.
8.1 For the 72-hour period of validity of a copy of an electronic medication chart, each page of the copy must include the following details of the chart:
(a) commencement time and date; and
(b) expiry time and date.
9.1 The copy of a chart requirements for a medication chart must include the chart identifier.
9.2 The copy of a chart requirements for a medication chart order must include:
(a) an identifier for each individual medication chart order represented as a token in the form of:
(i) DSPID in alpha numeric form; and
(ii) barcode; or QR code.
National Health (Pharmaceutical Benefits) Electronic National Residential Medication Charts Approval Instrument 2024
1 The whole of the instrument
Repeal the instrument.